ReviewExperimental and therapeutic medicine2020
Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review).
Review in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Real-Time Polymerase Chain Reaction in Detecting Active Hepatitis C Virus Infection: A Retrospective Analysis.Cureus · 2026Article
- Hepatitis C Virus Infection in Hemodialysis in Cameroon: Prevalence and Incidence.Journal of preventive medicine and hygiene · 2025Article
- Molecular prevalence and genotypic distribution of human pegivirus-1 among Iranian hemodialysis patients.Virus research · 2025Article
- Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India.BMC infectious diseases · 2025Observational
- Anti-hepatitis C virus threshold value in predicting hepatitis C virus viremia in hemodialysis patients.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria.BMC infectious diseases · 2024Article
- Prevalence and Genotypes of Hepatitis C Infection Among Hemodialysis Patients in Bushehr, Iran.Oman medical journal · 2023Article
- Prevalence of HBV, HCV, and HIV Infections among Patients Undergoing Hemodialysis in Fasa, Iran: A Six-Year Follow-up Study.Middle East journal of digestive diseases · 2022Article
- Impact of COVID-19 Infection on Liver Transplant Recipients: Does It Make Any Difference?Cureus · 2022Article
- An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease.Pathogens (Basel, Switzerland) · 2021Review
- Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma.Experimental and therapeutic medicine · 2021Article
- Hepatitis C virus and carpal tunnel syndrome in hemodialysis patients: a single center cross-sectional study.Renal failure · 2020Observational
- Tackling key immunological and immuno-dermatological pathways and their link to treatment options.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increase in the number of patients with chronic kidney disease (CKD) calls for improved management of these patients. In stage 5 CKD, when the initiation of renal replacement therapy (RRT) becomes necessary, there is an increase in the infection risk of the patients and immunological tests for hepatitis C virus (HCV) detection turn positive at an alarmingly higher rate compared to general population. With the introduction into clinical practice of diagnostic tests, the increased prevalence of HCV among CKD patients has been known since the 1990s. Also, the negative impacts of HCV infection on CKD evolution as well as the unfavorable evolution of grafts received by HCV infected patients are known. Chronic hemodialysis patients are a category of patients whose risk of HCV infection is substantial. Currently, in the hemodialysis centers, at the base of the transmission of HCV infection there are a multitude of factors. Infection with HCV has a different impact on patient with end-stage renal disease (ESRD). Comorbidities in this case have significant sources of mortality and morbidity. It was proven that the post transplantations problems were prevented and mortality was reduced for patients who were diagnosed with HCV and in whom the infection was treated before the kidney transplant (KT). Consequently, early detection of the infection and the application of specific treatment has a considerable impact on the outcome of the patients. Another important component of the management of HCV infection in the chronic hemodialysis patients is the prevention of the infection transmission by applying specific methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.